. MAG is commonly associated with chronic lung infections in susceptible hosts, such as cystic fibrosis (CF) (4), as well as wound infection and postsurgical site infections (5, 6). Macrolides such as clarithromycin and azithromycin are frequently the only oral antibiotics that are active against MAG and are commonly used to treat pulmonary infections (7, 8) . Members of the MAG differ in their susceptibility to clarithromycin. M. abscessus and M. bolletii, commonly display inducible macrolide resistance conferred by the ribosomal methyl transferase erm(41) gene (9). In contrast, most M. massiliense strains do not show inducible resistance due to a large, 274-bp deletion in the ribosomal methyl transferase erm(41) gene that renders it nonfunctional (9, 10), and clinical studies have shown a better response to clarithromycin in M. massiliense compared to M. abscessus (8, 10). Besides this major truncation, erm(41) can lose functionality by a T-to-C substitution at position 28 (T28C) yielding a Trp-to-Arg amino acid change (9, 11). The second mechanism of clarithromycin resistance is acquired through mutations in the drug-binding pocket of the 23S rRNA rrl gene at nucleotide positions 2058 and 2059 (12-15, 27). Phenotypic detection of clarithromycin resistance requires incubation of MAG with clarithromycin for up to 14 days. While MAG strains displaying acquired resistance show high MICs to clarithromycin after 3 to 5 days, those with an inducible active erm(41) gene typically show low MICs at 3 to 5 days and require longer incubation times (up to 14 days) for induction of resistance (16).
R
apidly growing mycobacteria (RGM) are important emerging human pathogens. Three closely related taxa of RGM with a controversial species/subspecies status-i.e., Mycobacterium abscessus subsp. abscessus (here M. abscessus), M. abscessus subsp. massiliense (M. massiliense), and M. abscessus subsp. bolletii (M. bolletii)-comprise the so-called "M. abscessus group" (MAG) (1) (2) (3) . MAG is commonly associated with chronic lung infections in susceptible hosts, such as cystic fibrosis (CF) (4) , as well as wound infection and postsurgical site infections (5, 6) . Macrolides such as clarithromycin and azithromycin are frequently the only oral antibiotics that are active against MAG and are commonly used to treat pulmonary infections (7, 8) . Members of the MAG differ in their susceptibility to clarithromycin. M. abscessus and M. bolletii, commonly display inducible macrolide resistance conferred by the ribosomal methyl transferase erm(41) gene (9) . In contrast, most M. massiliense strains do not show inducible resistance due to a large, 274-bp deletion in the ribosomal methyl transferase erm(41) gene that renders it nonfunctional (9, 10) , and clinical studies have shown a better response to clarithromycin in M. massiliense compared to M. abscessus (8, 10) . Besides this major truncation, erm(41) can lose functionality by a T-to-C substitution at position 28 (T28C) yielding a Trp-to-Arg amino acid change (9, 11) . The second mechanism of clarithromycin resistance is acquired through mutations in the drug-binding pocket of the 23S rRNA rrl gene at nucleotide positions 2058 and 2059 (12) (13) (14) (15) 27) . Phenotypic detection of clarithromycin resistance requires incubation of MAG with clarithromycin for up to 14 days. While MAG strains displaying acquired resistance show high MICs to clarithromycin after 3 to 5 days, those with an inducible active erm(41) gene typically show low MICs at 3 to 5 days and require longer incubation times (up to 14 days) for induction of resistance (16) .
Targeted sequencing is routinely used in the clinical laboratory to determine the intraspecies genetic diversity in mycobacterial isolates and discriminate among closely related taxa. Multiple genes, including rpoB, hsp65, secA, and others (17) (18) (19) (20) (21) (22) , as well as PCR-based assays (10, 23) have been evaluated as tools to discriminate between the closely related subspecies of the MAG. Since a truncated erm(41) gene was described as a hallmark of M. massiliense, size differences in PCR-amplified erm(41) PCR products were proposed as a simple method to differentiate M. massiliense from M. abscessus and M. bolletii (10) . However, this method can misclassify some strains, such as two recently described M. massiliense strains harboring a full-length and functional erm(41) gene (23) .
Since standard susceptibility testing of clarithromycin requires up to 14 days, there is a need for faster methods to detect clari-thromycin resistance. The present study describes the development and evaluation of two novel rapid real-time PCR assays for assessment of clarithromycin resistance on 87 clinical and 3 reference MAG strains. The first assay discriminates between full-length and truncated erm(41) based on differences in the melting temperature (T m ) of amplified products. The second assay identifies mutations associated with clarithromycin susceptibility and resistance using fluorescent locked nucleic acid (LNA) probes, including single nucleotide polymorphisms (SNPs) in the 23S rRNA rrl A2058G/C and A2058G positions (Escherichia coli rrl numbering) and T/C at the position 28 of the erm(41) gene. Our assays decreased the turnaround time of detection of resistance from 14 days to ϳ3 h, and results were concordant with targeted sequencing and phenotypic testing. This assay is feasible to use in laboratories set up to perform molecular tests and can help overcome technical challenges of determining MICs in slowly growing strains.
(This work was presented in part at the 115th T . The bacterial strains were stored at Ϫ80°C in Tween albumin broth (Remel, Thermo Scientific, Lenexa, KS). Prior to use, the organisms were subcultured onto Middlebrook 7H11 agar (Remel, Lenexa, KS).
DNA was extracted from a 10-l loopful of each mycobacterial colony with the Ultra Clean microbial DNA isolation kit (MoBio Laboratories, Solana Beach, CA), according to the manufacturer's instructions. Most clinical isolates before 2011 were previously identified by multilocus genomic sequencing with secA1, rpoB, and hsp65 (22) . More recent isolates were identified as MAG by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) followed by subspecies-level identification either by multilocus genomic sequencing (22) or a recently developed PCR method (23) . All primers (Table 1) and  probes (Table 2) in this study were purchased from IDT (Integrated DNA Technologies, Coralville, IA).
Real-time SYBR green assay to discriminate between full-length and truncated erm(41) genes. Primers erm225 and erm546Rev_RC (Table 1) were designed using the M. abscessus ATCC 19977
T genome erm(41) gene (MAB_2297), spanning the 274-bp region, which is truncated (nonfunctional) in most M. massiliense strains. The SYBR green assay was carried out in a 20-l reaction mixture, which consisted of 1 l of the forward and reverse primers (10 M stock) at a final concentration of 500 nm each and 2 to 3 l of genomic DNA (30 to 50 ng), nuclease-free water (5 to 6 l), and 10 l of the 2ϫ Fast SYBR green master mix (Thermo Fisher Scientific, Life Technologies, Grand Island, NY). The cycling conditions were as follows: a pre-PCR step of 95°C for 20 s followed by 40 cycles of 95°C for 10 s, 60°C for 30 s and 72°C for 30 s. This was followed by a melt curve step of 2 cycles of 95°C for 15 s and 60°C for 1 min in a 96-well PCR plate and processing on a 7500 Fast thermocycler (Thermo Fisher Scientific, Applied Biosystems, Grand Island, NY). The M. abscessus and M. massiliense type strains were used as positive controls for the full-length and truncated erm(41) genes, respectively. A negative control containing nucleasefree water instead of DNA template was included in all experiments. The reaction was set up in triplicate in a 96-well PCR plate and processed on a 7500 Fast thermocycler (Thermo Fisher Scientific, Applied Biosystems, Grand Island, NY). In silico PCR was done using NCBI BLASTn (http: //blast.ncbi.nlm.nih.gov/), and the publicly available M. abscessus ATCC Real-time 28C/T SNP detection in the inducible clarithromycin resistance erm(41) gene. Primers (MycoSNP_Fex and MycoSNP_Rex (Table 1) were designed using the M. abscessus ATCC 19977
T genome spanning a 124-bp region of the erm(41) gene containing the position 28 C/T SNP. Probes were reconstituted in Tris-EDTA (TE) buffer at a stock concentration of 100 M and stored at Ϫ70°C before use. The probes were then diluted to a working concentration of 10 M, with a final concentration in the reaction mixture of 250 nM for each probe. Allele-specific fluorescent-labeled LNA probes with a C or T nucleotide at position 28 of the erm(41) gene with LNA bases located on the SNP base and the flanking nucleotides were designed (probes T Allele and C Allele in Table 2 ). The SNP assay was carried out in a 20-l reaction mixture, which consisted of 1 l of the forward and reverse primers at a concentration of 20 M (1,000 nM final concentration), 0.5 l of each of the Allele T and Allele C LNA probes at a concentration of 10 m (250 nM final concentration), 2 to 3 l of genomic DNA (30 to 50 ng), nuclease-free water (5 to 6 l), and 10 l of the TaqMan GTXexpress master mix (Thermo Fisher Scientific, Life Technologies, Grand Island, NY). The reaction was set up in a 96-well PCR plate and processed on a 7500 Fast thermocycler (Applied Biosystems, Life Technologies, Grand Island, NY). The cycling conditions for the assays were a pre-PCR step at 95°C for 3 min, followed by 40 cycles of 95°C for 10 s, 60°C for 30 s, and 72°C for 30 s, followed by a post-PCR step at 72°C for 2 min. The extent of binding and the resulting fluorescence signal during the PCR at each time point are measured as Rn values for each probe (where Rn is the normalized reporter value). The fluorescence intensity for each probe is shown in allelic discrimination plots; the probe showing a high-intensity signal represents the allele on the DNA template. Allelic discrimination plots were generated using the Applied Biosystems 7500 Fast real-time PCR system software (Thermo Fisher Scientific, Applied Biosystems, Grand Island, NY).
Real-time single nucleotide polymorphism detection for acquired clarithromycin resistance on the rrl (23S rRNA) gene. Primers 23S_ SNPF and 23S_SNPR (Table 1) were designed using the M. abscessus ATCC genome 23S rRNA rrl gene (MAB_r5052). Allele-specific fluorescent-labeled LNA probes with the wild-type allele AA at nucleotides 2058 to 2059 and G or C at the nucleotide 2058 position or G at 2059 were designed (Table 2 ) with LNA bases located on the SNP base and the flanking bases. The SNP assay was carried out with the pairs WT_MAB and AA_2058G to detect the A2058G SNP, WT_MAB and AA_2058C to detect the A2058C SNP, and WT_MAB and AA_2059G to detect the A2059G SNP. The PCR, cycling conditions, and analysis of results were as described for the real-time 28C/T SNP detection assay.
Sequencing of the erm(41) and rrl genes to confirm deletions and SNPs. PCR was performed for the erm(41) and rrl genes on 87 clinical isolates and three reference strains using Qiagen Taq polymerase (Qiagen, Carlsbad, CA) in a 25-l total reaction volume consisting of 12.5 l master mix comprised of buffer, deoxynucleoside triphosphates (dNTPs), Taq polymerase, and 2 to 3 l (ϳ30 to 50 ng) of extracted DNA. Primers ermF and ermR1 (Table 1) (10) were used for amplification and sequencing of the erm(41) gene. Primers 23S_18 and 23S_21 were used for partial amplification of a region of the rrl gene spanning nucleotides 2058 and 2059, and sequencing was performed using the PCR primers and the internal primers 23SrRNAF_207 and 23SrRNAR_207. PCR products from the erm(41) and rrl genes were purified for sequencing using Amicon Ultra-0.5 ml 100K centrifugal filters (Millipore, Ltd., Carrigtwohill, Ireland). Sequencing of PCR amplicons was performed on the ABI Prism 3100 genetic analyzer (Applied Biosystems, Carlsbad, CA), and data were assembled using Lasergene SeqMan Pro technology (DNAStar, Inc., Madison, WI). Sequences were compared against the GenBank database using NCBI BLASTn (24; http://blast.ncbi.nlm.nih.gov/).
Clarithromycin susceptibility testing. Clarithromycin MIC values were determined in Mueller-Hinton medium by the broth microdilution method, using Sensititre RAPMYCO plates for strains isolated after July 2010 (Trek Diagnostic Systems, Thermo Fisher Scientific, Oakwood Village, OH). Earlier isolates were tested with frozen panels from PML Microbiologicals (Wilsonville, OR). Plates were evaluated at 3 to 5 days and were further incubated for 14 days at 30°C for a final reading to ensure detection of inducible resistance, according to the CLSI M24-A2 document (25) requiring extended incubation. The interpretative breakpoints used were those recommended by the CLSI (25): Յ2 g/ml, susceptible; 4 g/ml, intermediate; and Ն8 g/ml, resistant (see Table S1 in the supplemental material).
RESULTS
A total of 90 clinical and reference isolates of M. abscessus subspecies were used to develop and validate two real-time PCR-based assays aimed at the detection of clarithromycin resistance, which include differentiation between full-length and truncated inducible clarithromycin erm(41) and SNP detection in erm (41) Table S1 in the supplemental material). Most of the 69 isolates with the fulllength erm(41) gene were M. abscessus. Four isolates (CI5-9, CI7-8 CI20-27, and CI20-38) were identified as M. bolletii, and three isolates (CI20-39, CI20-40, and CI80-82) with full-length erm(41) were identified as M. massiliense.
Real-time assay for T/C SNP at position 28 of the erm(41) gene. Another mechanism by which the inducible clarithromycin erm(41) gene can lose functionality (besides a major truncation) is through a T-to-C substitution at position 28 (T28C) (9, 11) . The erm(41) SNP allele discrimination assay was designed to differentiate between both nucleotides at position 28. Out of a total of 90 isolates in this study, the majority had a T at position 28 (85/90 [95%]), and 5/90 (5%) had a C (see Table S1 in the supplemental material). Sixty-four of 69 isolates with full-length erm(41) contained a T at position 28 characteristic of active erm(41) genes, while 5/69 contained a C (strains CI6-2, CI6-6, CI7-9, CI12-1, and CI20-43-all M. abscessus). An allelic discrimination plot of T and C alleles at position 28 is shown in Fig. 2 . Isolates with T are seen in the far right quadrant along the x axis (CI6-3, CI20-19, CI20-25, CI20-30, CI20-31, CI20-35, CI20-36, CI20-37, CI20-38, CI20-42, and CI20-44), and an isolate with C is located in the upper left quadrant on the y axis. The negative control with water instead of genomic DNA is located in the left lower quadrant of the graph close to zero.
SNP assignment by this assay was confirmed by partial amplification and sequencing of erm(41). Susceptibility testing of most of the isolates with a T at position 28 of erm(41) yielded initial MIC values between 0.5 and 2.0 g/ml (susceptible) at 3 to 5 days and MIC values of Ն8 g/ml (resistant) at 14 days (see Table S1 in the supplemental material). Similar results were obtained with M. bolletii isolates (CI7-8, CI20-38, and CCUG 50184 T ) and M. massiliense full-length erm(41) isolates CI20-40 and CI81-82). In contrast, all 5 isolates with C at position 28 of erm(41) (CI6-2, CI6-6, CI7-9, CI12-1, and CI20-43) remained susceptible to clarithromycin even at 14 days incubation, with MIC values of 0.25 to 2.0 g/ml.
All 24 M. massiliense isolates in the study had a T at position 28, of which 21 harbored a truncated erm(41). Of the 21 strains with truncated erm(41), 13/21 (62%) had no acquired resistance and displayed clarithromycin MIC values of 0.12 to 0.5 g/ml at 3 to 5 days after the initial reading and remained susceptible to clarithromycin at 14 days.
Eight MAG isolates harboring a full erm(41) gene with T at position 28 and no SNPs associated with acquired resistance showed clarithromycin MICs above the susceptible range at the initial reading. These isolates were categorized into two groups: (i) isolates with a MIC of 4 (intermediate) to clarithromycin at the initial reading, including 3 M. abscessus strains CI20-2, CI20-15, and CI20-24, and (ii) isolates with a MIC of Ն8 (resistant) to clarithromycin at 3 to 5 days. This group includes 5 isolates: M. abscessus CI20-32, CI20-33, and CI20-44, M. bolletii isolate CI20-27, and M. massiliense isolate CI20-39.
Another noteworthy finding is the presence of very-slowgrowing MAG strains with a rough-colony morphology requiring 6 to 8 days of incubation for the first clarithromycin MIC reading, due to insufficient growth at 3 to 5 days. The slow-growing isolates in this group are M. abscessus CI20-2, CI20-6, CI20-8, CI20-10, CI20-11, and CI20-12. Interestingly, isolates CI20-2, CI20-6, CI20-8, and CI20-10 belong to 4 patients from which earlier isolates (7 to 11 years prior) with a standard growth pattern were available (CI20-1, CI20-5, CI20-7, and CI20-9, respectively) and were included in this study. Isolates CI20-11 and CI20-12 are an early strain and later strain from a 5th patient (5 years apart), both showing slow growth. All of these isolates showed inducible resistance to clarithromycin by day 14. Repeat antibiotic susceptibility tests on some of the slow-growing isolates showed faint growth in the positive-control well but no growth in any of the clarithromycin wells within the 5-day initial reading period. This highlights the technical difficulty in antibiotic susceptibility testing of slowly growing isolates. Real-time assays for 23S rRNA SNPs associated with acquired clarithromycin resistance. Allele determination for common mutations conferring acquired clarithromycin resistance in the 23S rRNA rrl gene was performed using probes targeting an A-to-G or -C change at position 2058 and an A-to-G change at position 2059. This assay was done in a pairwise manner in 3 reactions comprising WT_MAB with mutant probe AA_2058G, WT_MAB with mutant probe AA_2058C, and WT_MAB with mutant probe AA_2059G, respectively. We identified 15/90 (17%) isolates harboring resistance mutations in the 23S rRNA gene, including 11/90 (12%) isolates with the A2058G mutation comprising 8 M. massiliense isolates with a truncated erm(41) gene (CI6-14, CI6-15, CI7-3, CI1-1, CI20-42, CI15-1, CI20-26, and CI20-34) and 3 M. abscessus isolates with a full-length erm(41) gene (CI5-7, CI20-16, and CI20-18). Figure 3A is a representative allelic discrimination plot of an A or G SNP at position 2058, with isolate CI20-42 containing the 2058G mutation in the upper quadrant of the y axis, isolates with A at position 2058 (wild-type allele) in the far right quadrant of the x axis (CI20-19, CI20-30, CI20-31, CI20-35, CI20-38, CI20-43, and CI20-44, M. abscessus ATCC 19977 T ), and the negative control (water) or isolates with a different mutation (2058C or 2059G, strains CI6-3, CI20-25, CI20-36, and CI20-37) on the x-y coordinate close to zero. Three isolates in this study (CI6-3, CI20-25, and CI20-37) harbored the A2058C mutation in the 23S rRNA gene (Fig. 3B) , and one isolate (CI20-36) contained the A2059G mutation (Fig. 3C) . Again, strains harboring an SNP different from the wild type or the one assayed, A2058C (Fig. 3B) or A2059G (Fig. 3C) , respectively, clustered next to the negative control, close to zero. SNP assignments by these assays were confirmed by partial amplification and sequencing of the 23S rRNA gene.
All 15 isolates, M. abscessus or M. massiliense with rrl mutations conferring clarithromycin resistance, showed phenotypic resistance to clarithromycin at 3 to 5 days of incubation, with MIC values of Ն8 g/ml (see Table S1 in the supplemental material). There was 100% concordance between SNP assay results, sequencing of the 23S rRNA gene, and phenotypic detection of resistance by the broth microdilution method.
DISCUSSION
Macrolides such as clarithromycin and azithromycin are key antimicrobials in the treatment of pulmonary infections by members of the M. abscessus group (MAG) (7, 8, 26) . Clarithromycin resistance can be acquired via point mutations in the rrl gene encoding the peptidyl transferase domain of the 23S rRNA (27) via A2058G/C and/or A2059G transition or can be induced by the drug via a functional full-length inducible clarithromycin resistance erm(41) gene with a T at position 28 (9) . In this study, we developed a highly reproducible real-time PCR-based assay to differentiate between full-length and truncated erm(41) genes and SNP detection assays for mutations associated with clarithromycin resistance on the 23S rRNA and erm(41) genes using 87 clinical isolates of MAG obtained between 2005 and 2015 and 3 reference strains. All isolates were identified to the subspecies level by genomic sequencing and/or a PCR-based assay (23) .
Our SYBR green real-time PCR-based assay distinguished between the full-length (77%) and truncated (23%) erm(41) genes with a sensitivity of 100% compared to sequencing of the erm(41) gene. The assay is highly reproducible and does not require setting reactions with replicates based on the large, 7°C, difference in T m between the two products and the low standard deviation observed when tested in triplicate. Similarly, assignment of the T or C SNP at position 28 of erm(41) by our real-time SNP assay showed 100% concordance to erm(41) gene sequencing. In this study, the majority (93% [64/69]) of the isolates with full-length erm(41) had a T at position 28, and 7% (5/69) had a C. Thus, the rate of inactive C28 erm(41) in our study (7%) is lower than the recently reported rate of 18% of M. abscessus with an inactive C28 erm(41) sequevar (28) .
Current CLSI guideline M24-A2 (25) recommends reading the clarithromycin MIC at 3 days (or 4 or 5 days if there is insufficient growth) and a final reading at 14 days. All isolates in this study harboring full-length erm(41) with the T28 nucleotide (and no acquired resistance) showed inducible resistance to clarithromycin within 14 days. While most isolates showed MIC values of Յ2 g/ml (sensitive) in the first reading at 3 to 5 days, some strains showed a MIC of Ͼ2 (i.e., CI20-32, CI20-33, CI20-44, CI20-27, and CI20-39). One hypothesis is the possibility of an earlier induction of the erm(41) gene upon incubation with the drug for some strains. Another explanation lies in the technical challenges of this test. In a recent article, Brown-Elliott et al. (28) reported that some C28 isolates with a MIC of 8 upon extended incubation showed a MIC of Յ2 g/ml upon repeat testing. In the same study, the authors proposed to change clarithromycin susceptibility breakpoints from Յ2 g/ml to Յ4 g/ml. Using those newly proposed breakpoints, our 3 isolates with a MIC of 4 at 3 to 5 days would be considered susceptible at initial reading. In any case, more important than determination of the exact days of incubation at which inducible resistance appears is to make sure inducible resistance is phenotypically detected by day 14, when the final reading of the clarithromycin MIC occurs.
A more challenging issue is the slow-growing MAG strains often seen in multiply treated chronically infected patients for which incubation for 3 to 5 days in Mueller-Hinton broth yields insufficient growth for recording MICs and for which, according to CLSI M24-A2 (25), testing should be repeated. Examples of these isolates are CI20-2, CI20-6, CI20-8, and CI20-10. In the absence of guidelines for phenotypic testing of slowly growing isolates of MAG, sequencing of the erm(41) gene as suggested by BrownElliott et al. (28) could be particularly useful for predicting clarithromycin susceptibility patterns for these MAG strains.
In the work-up of cultures for identification and susceptibility testing, it is important to note any evidence of mixed populations on the culture plate reflecting a heterogeneous population of MAG in the patient sample. This is best illustrated by M. abscessus strains CI20-43 and CI20-44 and M. abscessus strains CI20-15 and CI20-16, which were coisolated on the same cultures from sputum samples. CI20-43 is a smooth-colony-morphology strain that harbors a C28-inactive erm(41) gene and remains sensitive to clarithromycin upon extended incubation, while the rough morphotype CI20-44 contains a T28-active erm(41) gene conferring inducible resistance to the clarithromycin MIC. Isolate CI20-15 is a rough-colony-morphology isolate with an active erm(41) gene and no mutational resistance, while CI20-16 is a smooth-colonymorphology isolate with acquired mutational resistance to clarithromycin (A2058G mutation in the 23S rRNA gene).
In this study, we have identified 15 (out of 90 MAG) isolates with mutations on the 23S rRNA gene comprising 7/61 (11%) M. abscessus and 8/24 (33%) M. massiliense. The most common mutation was A2058G, seen in all M. massiliense isolates and 3 M. abscessus isolates with acquired resistance, followed by A2058C (three M. abscessus isolates) and A2059G (one M. abscessus isolate). The high frequency of mutational resistance among M. massiliense isolates should not be surprising, as this is the only known mechanism of resistance available for organisms harboring a truncated erm(41) gene. This study included early (CI15-4 and CI20-41) and late (CI15-1 and CI20-42) M. massiliense isolates (4 to 7 years apart) from the 2 cystic fibrosis (CF) patients. Early isolates were susceptible to clarithromycin, with MIC values of 0.25 g/ml after 14 days of incubation, as expected for strains harboring truncated erm(41) genes; however, late isolates from each patient showed MIC values of Ͼ16 g/ml due to the acquisition of the A2058G mutation on the 23S rRNA gene. Acquisition of mutational resistance to clarithromycin on patients treated with macrolides has been documented in serial isolates of M. abscessus (29) and M. massiliense (2) . Our study confirms this finding with these 2 CF patients who received prolonged treatment with azithromycin and/or clarithromycin.
There are few studies describing molecular assays for clarithromycin resistance that are amenable to implementation in a clinical laboratory. In a recent study, Lee et al. (30) described an amplification refractory mutation system and PCR (ARMS-PCR) and a real-time PCR melting peak analysis method for detection of erm(41) T28 and C28 mutations in M. abscessus clinical isolates. The ARMS-PCR method (cheaper but more time-consuming than real-time PCR) detected all 17 C28 isolates and all 140 T28 isolates, in agreement with sequence analysis, which was used as a reference standard. Their real-time PCR melting peak method also detected all 17 C28 isolates; however, the authors only reported the results from 50 of the 140 T28 isolates. Curry et al. developed a real-time assay consisting of two duplex PCRs for identification of both erm(41) and rrl clarithromycin mutations using SYBR green chemistry and melt curve analysis (C. Curry, R. Luo, and N. Banaei, poster 118, presented at the 114th General Meeting of the American Society for Microbiology, Boston, MA, 17 to 20 May 2014). Phenotypic testing (either Etest or broth MIC) was used as the reference standard to define clarithromycin resistance. They reported a sensitivity of 88% (23/26 isolates) for detection of resistance due to a functional erm(41) gene and 100% sensitivity for detection of isolates with a nonfunctional or truncated erm(41) gene in 37/37 isolates. The assay was 100% sensitive in detecting rrl mutations in 3/3 isolates.
In our study, the SYBR green and position 28 T/C SNP realtime PCR-based assays were 100% sensitive in differentiating between functional and nonfunctional erm(41) compared to erm(41) gene sequencing and correctly predicted the presence and absence of inducible clarithromycin resistance by phenotypic testing. These assays were particularly helpful for predicting resistance in slowly growing strains of MAG. Our real-time SNP assay for acquired mutational clarithromycin resistance in the 23S rRNA gene was 100% sensitive compared to 23S rRNA gene sequencing and also predicted the phenotypic resistance observed in all 15 strains. Of note, both the RAPMYCO and PML Microbiologicals susceptibility testing systems test a limited range of clarithromycin MIC values (up to 8 or 16 g/ml) far below the MICs (Ͼ128 g/ml) reported in MAG with 23S rRNA mutations (10, 11, 27) .
Based on this study, our proposed testing algorithm includes an initial assessment of the full or truncated erm(41) gene using the SYBR green assay followed by SNP detection in isolates that have an intact erm(41) gene for the presence of a C or T base at position 28. This is followed by detection of SNPs of acquired clarithromycin resistance in the 23S rRNA gene. The most common mutation in this cohort was the A2058G substitution on the 23S rRNA gene and should be tested first. Moreover, the A2058G SNP assay by itself will also distinguish non-wild-type isolates with other mutations at position 2058 and/or 2059, as they will be clustering with the negative control in SNP allelic discrimination plots. In conclusion, our real-time melting curve analysis and SNP detection assays for inducible and acquired clarithromycin resistance are easy to implement in the laboratory and provide clinically useful results within ϳ3 h, a significant improvement in turnaround time compared to the 14-day incubation required by phenotypic detection of resistance by broth microdilution.
